Imaging of bone sarcomas

Bone sarcomas, mesenchymal origin tumors, represent a substantial group of varying neoplasms of a distinct entity. Bone sarcoma patients show a limited response or do not respond to chemotherapy. Notably, developing efficient chemotherapy approaches, dealing with chemoresistance, and preventing metastasis pose unmet challenges in sarcoma therapy. Insulin-like growth factors 1 and 2 (IGF-1 and -2) and their respective receptors are a multifactorial system that significantly contributes to bone sarcoma pathogenesis. Whereas failures have been registered in creating novel targeted therapeutics aiming at the IGF pathway, new agent development should continue, evaluating combinatorial strategies for enhancing antitumor responses and better classifying the patients that could best benefit from these therapies. A plausible approach for developing a combinatorial strategy is to focus on the tumor microenvironment (TME) and processes executed therein. Herewith, we will discuss how the interplay between IGF-signaling and the TME constituents affects sarcomas’ basal functions and their response to therapy. This review highlights key studies focusing on IGF signaling in bone sarcomas, specifically studies underscoring novel properties that make this system an attractive therapeutic target and identifies new relationships that may be exploited. Potential direct and adjunct therapeutical implications of the extracellular matrix (ECM) effectors will also be summarized.

Download Full-text

The growth rate of bone sarcomas and survival after radiotherapy with tourniquet-induced hypoxia: A clinical study

Cancer ◽

10.1002/1097-0142(19820415)49:8<1597::aid-cncr2820490812>3.0.co;2-g ◽

1982 ◽

Vol 49 (8) ◽

pp. 1597-1604 ◽

Cited By ~ 4

Author(s):

Saim B. Balmukhanov ◽

Ismahsam Turdugulov ◽

Zaida Karibjanova ◽

László Révész

Keyword(s):

Growth Rate ◽

Clinical Study ◽

Bone Sarcomas

Download Full-text

Imaging of Bone Sarcomas and Soft-Tissue Sarcomas

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren ◽

10.1055/a-1401-0215 ◽

2021 ◽

Author(s):

Jasminka Igrec ◽

Michael H. Fuchsjäger

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcomas ◽

Bone Cancer ◽

Bone Sarcoma ◽

Daily Practice ◽

Imaging Evaluation ◽

Key Points ◽

Bone Sarcomas ◽

Publication Period ◽

Ct And Mri

Background In the diagnosis of bone and soft-tissue sarcomas, the continuous advancement of various imaging modalities has improved the detection of small lesions, surgical planning, assessment of chemotherapeutic effects, and, importantly, guidance for surgery or biopsy. Method This review was composed based on a PubMed literature search for the terms “bone sarcoma,” “bone cancer” and “soft tissue sarcoma,” “imaging,” “magnetic resonance imaging”, “computed tomography”, “ultrasound”, “radiography”, and “radiomics” covering the publication period 2005–2020. Results and Conclusion As discussed in this review, radiography, ultrasound, CT, and MRI all play key roles in the imaging evaluation of bone and soft-tissue sarcomas. In daily practice, advanced MRI techniques complement standard MRI but remain underused, as they are considered time-consuming, technically challenging, and not reliable enough to replace biopsy and histology. PET/MRI and radiomics have shown promise regarding the imaging of sarcomas in the future. Key Points: Citation Format

Download Full-text